Arena Pharmaceuticals' Q1 Loss Widens 34% Despite Belviq's Sales Surge

Arena Pharmaceuticals (NASDAQ: ARNA  ) , a biopharmaceutical company primarily focused on weight control management drug Belviq, this afternoon reported strong sales growth of its lead product in the first quarter, but also produced a much wider net loss than in the prior-year period.

For the quarter, Arena delivered $6.8 million in revenue, up 187% from the prior-year period as it recognized $2.9 million in Belviq net product sales (representing its 31.5% share of partner Eisai Pharmaceuticals' reported $8.4 million in total sales) compared to $0 in Q1 2013, and saw its collaborative revenue with Eisai more than double to $3.3 million from $1.5 million. As noted in the report, Belviq prescriptions written surged 31% to 77,000 in Q1 with more than 60% of people in the U.S. now estimated to be insurance eligible in some way to receive Belviq.

However, costs associated with Belviq and the remainder of Arena's pipeline also rose, sending research and development expenses up to $21 million from $14 million in the year-ago quarter, and pushing total operating expenses higher by 30% to $30.4 million.

Net loss for the quarter widened by 34% to $25.3 million, or $0.12 per share, from $18.9 million, or $0.09 per share in the year-ago quarter. By comparison, Wall Street was anticipating a slightly narrower loss of just $0.10 per share.

Lastly, Arena announced that it ended the quarter with $256.5 million in cash, cash equivalents, and short-term investments, up from the $221.9 million reported in the sequential fourth quarter. 


Read/Post Comments (6) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 12, 2014, at 4:57 PM, marp11 wrote:

    keep shorting

  • Report this Comment On May 12, 2014, at 4:57 PM, billcatedit wrote:

    The 8-K looks good! You say it yourself:

    As noted in the report, Belviq prescriptions written surged 31% to 77,000 in Q1 with more than 60% of people in the U.S. now estimated to be insurance eligible in some way to receive Belviq.

    Arena announced that it ended the quarter with $256.5 million in cash, cash equivalents, and short-term investments, up from the $221.9 million reported in the sequential fourth quarter

  • Report this Comment On May 12, 2014, at 4:58 PM, marp11 wrote:

    10q only shows 1.56 BILLION DUE FOR EISAI

    in PPA'S..

    but please keep bashing and please stay short

    or but VVUS AND OREX may be better fir you hf;s

  • Report this Comment On May 12, 2014, at 4:59 PM, marp11 wrote:

    scrips will be up near 100% in quarter 2 at the least

    motley fools good name

  • Report this Comment On May 12, 2014, at 5:30 PM, Tanis2476 wrote:

    Love how you just dismissively throw in the fact that cash and equivalents INCREASED BY $35,000,000 at the end of the article after bashing ARNA in both the title and majority of the "article."

    Keep it coming....

  • Report this Comment On May 13, 2014, at 4:16 AM, marp11 wrote:

    We intend to enter into additional collaborative agreements for the potential regulatory approval and commercialization of BELVIQ in Australia, New Zealand and Israel.

    more $$$$

    EU will be begging for their BELVIQ just for the smoking cessaton.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2954180, ~/Articles/ArticleHandler.aspx, 10/20/2014 4:14:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement